Evidence map›Paper›PMID 39951214›Full record

ArticleAdvances in therapy2025

Liver-Kidney-Metabolic Health, Sex, and Menopause Impact Total Scores and Monovessel vs. Multivessel Coronary Artery Calcification.

Kamran Bagheri Lankarani, Mohamad Jamalinia, Fatemeh Zare, Seyed Taghi Heydari, Ali Ardekani, Amedeo Lonardo

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2025
    Review
  9. The Ovary-Liver Axis: Molecular Science and Epidemiology.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kamran Bagheri LankaraniHealth Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohamad JamaliniaGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. mohamadjamalinia@gmail.com.ORCID 0000-0002-1645-9989
Fatemeh ZareGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Taghi HeydariHealth Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali ArdekaniHealth Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Amedeo LonardoDepartment of Internal Medicine, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.

Funding

Shiraz University of Medical Sciences 24616
6 · The paper itself

Abstract

introductionLiver-kidney-metabolic health (LKMH) depends on complex interactions between metabolic dysfunction-associated steatotic liver disease (MASLD), chronic kidney disease (CKD), sex, and reproductive status. This study evaluates in a holistic manner how LKMH, sex, and menopause influence coronary artery calcification (CAC) burden.

methodsPatients without previous cardiovascular disease were prospectively recruited. Liver fat was assessed via ultrasonography and categorized as mild or moderate-to-severe. CKD was classified using estimated glomerular filtration rate (eGFR). CAC burden was quantified as 0, 1-299, ≥ 300, single-vessel, or multivessel with coronary computed tomography. Stepwise backward multinomial logistic regression was applied for analysis.

resultsA total of 446 patients (59.2% female, average age 52.9 years) were included. Moderate-to-severe MASLD was independently associated with an increased risk of CAC 1-299 [OR 2.30 (1.21-4.36)], CAC ≥ 300 [OR 4.93 (1.46-16.59)], and single-vessel CAC [OR 2.03 (1.03-4.00)]. Mild MASLD [OR 2.47 (1.20-4.21)], moderate-to-severe MASLD [OR 3.74 (1.76-7.93)], and CKD stage 2 [OR 2.27 (1.26-4.08)] were independently associated with increased multivessel CAC risk. Liver fat content showed a dose-response association with CAC burden. Subgroup analysis revealed that MASLD and CKD increased CAC risk in male but not female patients, with menopause significantly modifying LKMH's effect.

conclusionLKMH's impact on CAC burden is significantly influenced by liver fat content, eGFR, sex, and menopause, suggesting that MASLD, CKD, sex, and reproductive status should be integrated into CAC risk prediction models.

Indexed as

Coronary Artery DiseaseMenopauseNon-alcoholic Fatty Liver DiseaseRenal Insufficiency, ChronicVascular CalcificationAdultAgedFemaleGlomerular Filtration RateHumansLiverMaleMiddle AgedProspective StudiesRisk FactorsSex FactorsCardiovascular-kidney-metabolic syndromeCardiovascular riskCoronary artery diseaseLiver fat contentMenopauseMetabolic dysfunctionNonalcoholic fatty liver diseaseSex differencesSubclinical atherosclerosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.